US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
Women can stand the cold BETTER than men, surprising study finds
It's long been thought that women feel the cold more than men.But a new study suggests otherwise – a2024-05-01Luton loses at Wolves in another blow to survival bid in EPL
WOLVERHAMPTON, England (AP) — Luton’s survival bid in the English Premier League took another hit af2024-05-01Sen. Alex Padilla emerges as persistent counterforce for immigrants
WASHINGTON (AP) — President Joe Biden had a question.“Is it true?” Biden asked Sen. Alex Padilla, re2024-05-01Ukraine pushes to get military
KYIV, Ukraine (AP) — Ukraine’s foreign minister doubled down Friday on the government’s move to bols2024-05-01Malian army says it killed an Islamic State group commander who attacked U.S., Niger forces
BAMAKO, Mali (AP) — A senior Islamic State group commander wanted in connection with the deaths of U2024-05-01- Ryan Giggs' ex-wife is said to 'approve' of the footballer's girlfriend Zara Charles. Stacey Giggs,2024-05-01
atest comment